CREBBP and lymphoma: Without jumping to conclusions, it would be interesting to know if mutations that result in decreased or lost KMT2D expression in GC B-cells also result in decreased CREBBP/P300 recruitment to and activation of enhancers in GC B-cells and/or lymphoma.